Issue link: https://www.e-digitaleditions.com/i/1520859
12 Pharmaceutical Technology ® Trends in Manufacturing eBook May 2024 PharmTech.com Exploring Multimodal Biomanufacturing and Its Drivers Jeff Odum, CPIP, is practice lead, ATMPs & Biologics, at Genesis AEC. A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety. M ultimodal manufacturing is a strategic ap- proach that harnesses the power of diverse manufacturing methods to optimize and streamline the production process, specif- ically within the realm of human therapeutics in the advanced therapy medicinal products (ATMP) space. This concept involves integrating different manufac- turing techniques/platforms to improve efficiency, reduce costs, and enhance the overall quality of the manufacturing process and the eventual therapeutic product slated for licensure. In a White House report, Bold Goals for US Biotech- nology and Biomanufacturing, a prominent objective is to test and de-risk new biomanufacturing practices for next-generation biotechnology products in com- mercial manufacturing facilities (1). The growing focus in cell-based therapies, a key component of the next generation of human therapeutics, has led many organizations to focus their development efforts into a multitude of platforms. Multimodal is not new. For the ATMP space, it was identified back in 2017 as a viable manufacturing op- tion for clinical needs. In the context of the biotech- nology ATMP space, multimodal manufacturing tech- niques are being applied to optimize the production of complex biological compounds and therapies that are studied in multi-omic research, such as gene editing (1). In reality, many contract development and man- ufacturing organizations have been operating in a quasi-multimodal manner for decades. Multimodal can include vaccines, monoclonal antibodies (mAbs), viral vectors, plasmids, allogeneic cell therapies, and MUHAMMAD- STOCK.ADOBE,COM